Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anti-NGFs Advisory Committee Postponed As FDA Reviews New Information

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency is assessing safety signals for the biologics, which are being developed for chronic pain.
Advertisement

Related Content

Anti-NGF Drugs Clinical Holds Could Depend On What FDA Panel Thinks Of Standard Of Care
Anti-Nerve Growth Factor Developers Face Go/No-Go Recommendation From Advisory Panel
Creabilis Pulls In Corporate VC With €15M Series B
Creabilis Pulls In Corporate VC With €15M Series B
Regeneron, J&J, AstraZeneca Pull Plug On NGF Inhibitors In Development For Pain Indications

Topics

Advertisement
UsernamePublicRestriction

Register

PS072658

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel